It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INMB’s FA Score shows that 0 FA rating(s) are green whileUAL’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INMB’s TA Score shows that 6 TA indicator(s) are bullish while UAL’s TA Score has 5 bullish TA indicator(s).
INMB (@Biotechnology) experienced а -0.85% price change this week, while UAL (@Airlines) price change was +10.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.
The average weekly price growth across all stocks in the @Airlines industry was -0.55%. For the same industry, the average monthly price growth was +11.86%, and the average quarterly price growth was +105.13%.
INMB is expected to report earnings on Oct 29, 2025.
UAL is expected to report earnings on Oct 21, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Airlines (-0.55% weekly)Airlines industry comprises passenger air transportation, including scheduled and non-scheduled routes. This can include charter airlines, as well as regular commuter ones. Discount pricing and the rise of low-cost carriers over recent decades have expanded the industry by making its services accessible to a much larger global population, compared to the older days when airline travel was a relative luxury for many people in the world. Delta Air Lines Inc., Southwest Airlines Co and United Continental Holdings, Inc. are some of the airlines with the largest stock market capitalizations in the U.S.
INMB | UAL | INMB / UAL | |
Capitalization | 63.7M | 29.8B | 0% |
EBITDA | -41.52M | 6.13B | -1% |
Gain YTD | -49.893 | -8.888 | 561% |
P/E Ratio | N/A | 9.15 | - |
Revenue | 50K | 57.7B | 0% |
Total Cash | 19.3M | 15.3B | 0% |
Total Debt | 347K | 32.9B | 0% |
INMB | UAL | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 1 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 45 | |
SMR RATING 1..100 | 99 | 29 | |
PRICE GROWTH RATING 1..100 | 98 | 40 | |
P/E GROWTH RATING 1..100 | 100 | 16 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INMB's Valuation (81) in the Biotechnology industry is in the same range as UAL (91) in the Airlines industry. This means that INMB’s stock grew similarly to UAL’s over the last 12 months.
UAL's Profit vs Risk Rating (45) in the Airlines industry is somewhat better than the same rating for INMB (100) in the Biotechnology industry. This means that UAL’s stock grew somewhat faster than INMB’s over the last 12 months.
UAL's SMR Rating (29) in the Airlines industry is significantly better than the same rating for INMB (99) in the Biotechnology industry. This means that UAL’s stock grew significantly faster than INMB’s over the last 12 months.
UAL's Price Growth Rating (40) in the Airlines industry is somewhat better than the same rating for INMB (98) in the Biotechnology industry. This means that UAL’s stock grew somewhat faster than INMB’s over the last 12 months.
UAL's P/E Growth Rating (16) in the Airlines industry is significantly better than the same rating for INMB (100) in the Biotechnology industry. This means that UAL’s stock grew significantly faster than INMB’s over the last 12 months.
INMB | UAL | |
---|---|---|
RSI ODDS (%) | 2 days ago90% | 2 days ago77% |
Stochastic ODDS (%) | 2 days ago82% | 2 days ago72% |
Momentum ODDS (%) | 2 days ago74% | 2 days ago78% |
MACD ODDS (%) | 2 days ago86% | 2 days ago76% |
TrendWeek ODDS (%) | 2 days ago88% | 2 days ago80% |
TrendMonth ODDS (%) | 2 days ago89% | 2 days ago80% |
Advances ODDS (%) | 15 days ago83% | 15 days ago75% |
Declines ODDS (%) | 3 days ago87% | N/A |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago68% |
Aroon ODDS (%) | 2 days ago88% | 3 days ago73% |
A.I.dvisor indicates that over the last year, INMB has been loosely correlated with ORMP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then ORMP could also see price increases.
Ticker / NAME | Correlation To INMB | 1D Price Change % | ||
---|---|---|---|---|
INMB | 100% | +13.04% | ||
ORMP - INMB | 38% Loosely correlated | +0.96% | ||
AXON - INMB | 37% Loosely correlated | -0.42% | ||
ABCL - INMB | 37% Loosely correlated | +3.05% | ||
PROK - INMB | 35% Loosely correlated | +10.68% | ||
CGEN - INMB | 34% Loosely correlated | N/A | ||
More |